Brief report: Psychopharmacology of autism spectrum disorders

Journal of Autism and Developmental Disorders

Volumn 26, Issue 2, 1996, Pages 231-235

  Lewis, Mark H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOMIPRAMINE; CLONIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; FENFLURAMINE; FLUOXETINE; HALOPERIDOL; OPIATE ANTAGONIST; OXYTOCIN; SEROTONIN UPTAKE INHIBITOR; VASOPRESSIN;

AUTISM; CONFERENCE PAPER; DRUG EFFECT; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ANIMALS; AUTISTIC DISORDER; BRAIN; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; HUMANS; INFANT; PSYCHOTROPIC DRUGS; RECEPTORS, NEUROTRANSMITTER; TREATMENT OUTCOME;

EID: 0029875873     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02172018     Document Type: Conference Paper

References (11)

1. Aman, M. G., & Kern, R. A. (1989). Review of fenfluramine in the treatment of the developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 549-565.
2. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of halperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640-655.
3. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283-1291.
4. Chamberlain, R. S., & Herman, B. H. (1990). A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biological Psychiatry, 28, 773-793.
5. Cook, E. H. J., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739-745.
6. Gillberg, C. (1995). Endogenous opioids and opiate antagonists in autism: Brief review of empirical findings and implications for clinicians. Developmental Medicine and Child Neurology, 37, 239-245.
7. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363-366.
8. Lewis, M. H., Bodfish, J. W., Powell, S. B., & Golden, R. N. (1995). Clomipramine treatment for repetitive movement disorders in mental retardation: A double-blind comparison with placebo. American Journal on Mental Retardation, 100, 299-312.
9. Lewis, M. H., Gluck, J. P., Bodfish, J. W., Beauchamp, A. J., Beauchamp, A. J., & Mailman, R. B. (in press). Neurobiological basis of stereotyped movement disorder in animals and humans. In R. L. Sprague & K. M. Newell (Eds.), Stereotypy: Brain behavior relationships. Washington, DC: American Psychological Association.
10. McDougle, C. J., Price, L. H., & Volkmar, F. R. (1994). Recent advances in the pharmacotherapy of autism and related conditions. Child and Adolescent Psychiatric Clinics of North America, 3, 71-89.
11. McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O'Brien, D., Nielsen, J., Bregman J., & Cohen, D. J. (1992). Clomipramine in autism: Preliminary evidence of efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 746-750.